Axl/Mer/CSF1R selective tyrosine kinase inhibitor

· Qurient Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Axl/Mer/CSF1R selective tyrosine kinase inhibitor, covering 2025-12-30 to 2025-12-30. Get the full timeline:

Most recent: Clinical Trial Update: Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor [Phase 1]